Date: 2017-05-08
Type of information: Distribution agreement
Compound: Bronchitol® (mannitol)
Company: Pharmaxis (Australia) Chiesi (Italy)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: distribution
Action mechanism: Bronchitol® is a precision spray-dried form of mannitol, delivered to the lungs by a specially designed, portable inhaler.
Disease: cystic fibrosis
Details: • On May 8, 2017, Pharmaxis announced it has entered into an exclusive distribution and supply agreement with Chiesi Farmaceutici for the commercialisation of Bronchitol® (mannitol) for cystic fibrosis in adults aged 18 years and above in Chiesi’s home market of Italy. Under the terms of the agreement Chiesi will take over responsibility for the marketing, sales and distribution of Bronchitol with immediate effect. Italy has approximately 5,000 cystic fibrosis patients and is one of the top 5 EU markets by value. This new territory has been added as an extension to the agreement signed with Chiesi in 2015 for distribution rights in Germany, Ireland and the United Kingdom. Pharmaxis continues to manufacture Bronchitol on commercial terms for Chiesi and the two parties are in the final stages of extending the exclusive supply agreement to 2024 for these markets and the United States.
Financial terms:
Latest news:
